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Human breast cancer-derived 
soluble factors facilitate CCL19-
induced chemotaxis of human 
dendritic cells
Hyundoo Hwang1,*, Changsik Shin2,*, Juhee Park2,*, Enoch Kang1,3, Bongseo Choi4,  
Jae-A Han4, Yoonkyung Do4, Seongho Ryu5 & Yoon-Kyoung Cho2,4
Breast cancer remains as a challenging disease with high mortality in women. Increasing evidence 
points the importance of understanding a crosstalk between breast cancers and immune cells, but 
little is known about the effect of breast cancer-derived factors on the migratory properties of dendritic 
cells (DCs) and their consequent capability in inducing T cell immune responses. Utilizing a unique 3D 
microfluidic device, we here showed that breast cancers (MCF-7, MDA-MB-231, MDA-MB-436 and SK-
BR-3)-derived soluble factors increase the migration of DCs toward CCL19. The enhanced migration 
of DCs was mainly mediated via the highly activated JNK/c-Jun signaling pathway, increasing their 
directional persistence, while the velocity of DCs was not influenced, particularly when they were co-
cultured with triple negative breast cancer cells (TNBCs or MDA-MB-231 and MDA-MB-436). The DCs 
up-regulated inflammatory cytokines IL-1β and IL-6 and induced T cells more proliferative and resistant 
against activation-induced cell death (AICD), which secret high levels of inflammatory cytokines IL-1β, 
IL-6 and IFN-γ. This study demonstrated new possible evasion strategy of TNBCs utilizing their soluble 
factors that exploit the directionality of DCs toward chemokine responses, leading to the building of 
inflammatory milieu which may support their own growth.
The tumor microenvironment is the site where tumors develop through complicated interactions between tumor 
cells and various cells within or surrounding tumor nests, such as stromal cells, innate immune cells, and lym-
phocytes1. Complex multi-factors derived from the tumor microenvironment and various immune responses 
in the tumor microenvironment can often influence clinical outcomes, resulting either in tumor rejection or 
tumor promotion2,3. Since dendritic cells (DCs) play a key role in the initiation and regulation of antigen-specific 
immune responses4,5, the roles of DCs in the tumor microenvironment and their immune consequences have 
been actively investigated6. Tissue-resident immature DCs continuously take up and process antigens, and upon 
encountering danger signals, these antigen-bearing DCs undergo a maturation process expressing CCR7 and 
migrate responding to their ligand CCL19 or CCL21 into the T cell enriched-area of secondary lymphoid organs7. 
Here, the mature DCs present the processed antigens to T cells, leading to T cell priming and differentiation8. 
Thus, DCs play a major role as a sentinel in cancer immunosurveillance and are capable of initiating anti-tumor 
immune responses. In fact, the infiltration of DCs into primary tumor lesions has been associated with prolonged 
survival and better clinical outcomes in many different types of cancers9. In contrast, altered maturation and dys-
functional DCs have been reported to occur in cancer patients and diverse strategies of tumors to evade, suppress, 
or tolerate the anti-tumor activity of DCs have been proposed10,11.
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A deficiency in mature DC (mDC) infiltration into primary breast tumor sites and dysfunctional DCs isolated 
from breast cancer patients have also been reported12, which may explain the poor immunogenicity of breast 
cancers. Immature CD1a+Langerin+ DCs have been found within these tumors, whereas mature CD83+Lamp+ 
DCs have been located in peritumoral areas13. Moreover, deficiency of the active form of DCs has been observed 
in the breast cancer microenvironment14. When DCs were isolated either from peripheral blood or lymph nodes 
of breast cancer patients, impaired maturation and reduced T cell stimulatory activity of DCs were observed15,16 
and these cells were more susceptible to spontaneous apoptosis in comparison to those from healthy volunteers17. 
Nonetheless, unlike other tumor types, no positive correlation between infiltration of DCs in the breast cancer 
microenvironment and survival of cancer patients or better outcomes have been reported18–20. These discrepant 
findings prompted us to investigate the unknown effects of breast cancer-derived factors on the migratory fea-
tures of DCs followed by their ability in inducing T cell immune responses. In addition, studies reported that 
the main cause of death was not due to primary breast cancers but due to their metastases at certain sites21,22. 
However, it has not been clearly explained whether there are altered functions or migratory properties of DCs 
particularly by breast cancers-derived factors.
In this study, we utilized single cell-based analysis in a 3D microfluidic device and observed that soluble fac-
tors secreted from breast cancer cell lines increased CCL19-induced directional persistence of human DCs. We 
found that the triple negative breast cancer (TNBC) cells such as MDA-MB-231 and MDA-MB-436 facilitate the 
CCL19-induced directional movement of human DCs via highly up-regulated the JNK/c-Jun signaling pathway. 
We also demonstrated that TNBC-affected DCs secrete pro-inflammatory cytokines and T cells that have been 
induced by these DCs are highly proliferative and are resistant to activation-induced cell death (AICD) while 
secreting profound pro-inflammatory cytokines, building host inflammatory milieu that may support tumor 
growth.
Results
3D microfluidic device was utilized to examine the chemotaxis and chemokinesis of DCs. To 
investigate whether the chemotaxis or chemokinesis of DCs are influenced by human breast cancer-derived sol-
uble factors, a 3D microfluidic device was applied to construct an in vitro microenvironment under a stable 
chemical concentration gradient (Fig. 1a). Microchannels comprising three different levels were fabricated by 
molding poly(dimethylsiloxane) (PDMS) with a multilayer-stack of plotter-cut adhesive tapes (Supplementary 
Fig. S1)23. This multilevel channel design provides substantial advantages for on-chip cell migration assays—such 
as cleanroom-free device fabrication and pipette-based sample delivery. In addition, tracking the movements 
of individual cells in the microfluidic device allowed us to analyze their migration quantitatively, thus provid-
ing more detailed information about cellular behavior, which cannot be obtained by using traditional transwell 
migration assays24.
Here, 1 μ L collagen gel, containing DCs, was loaded into the shallowest main channel, while two side-channels 
adjacent to the main channel were filled with 1% agarose gel. The human monocyte-derived DCs were prepared 
and matured with 25 μ g/ml poly (I:C), a DC maturation stimulus, before loading into the chip. A linear concen-
tration gradient of CCL19 was formed across the collagen gel by loading a 3 μ g/ml CCL19 solution into the media 
chamber (Fig. 1a). The gradient of CCL19 within the collagen gel was expected to be around 1.8 μ g/ml per mm, 
as determined by numerical simulation (Supplementary Fig. S2). The positions of individual DCs were recorded 
every 2 min and were tracked for 2 h (Fig. 1b). The mDCs tended to migrate toward the high CCL19 concentra-
tion of the gradient, while they showed random movements in the absence of the gradient (Fig. 1c,d). From the 
cell trajectory data, the velocity and directional persistence of each cell could be calculated quantitatively as s/t 
and d/s, respectively, where s is the total distance of the traveled cell, t is the total time the cell was tracked, and d 
is the displacement along the gradient axis (Fig. 1e). ImDCs were devoid of directionality, regardless of the pres-
ence of the CCL19 gradient. Both the velocity and directional persistence of mDCs were significantly increased 
in the presence of the CCL19 gradient (Fig. 1f,g). Based on these results, we confirmed that CCL19 induces both 
chemokinesis and chemotaxis of human mDCs, which is consistent with the previous studies25,26. Our results also 
indicated that the multilevel microfluidic device offers reliable quantitative data collection, and thus is applicable 
for the study of the effect of breast cancer-derived soluble factors on CCL19-induced DC chemotaxis.
Breast cancer-derived soluble factors facilitate the directional movement of DCs toward 
CCL19. To investigate the effects of human breast cancer-derived factors on DCs, we utilized four different 
types of breast cancer cell lines: epithelial MCF-10A; luminal MCF-7; two different metastatic TNBC cell lines, 
MDA-MB-231 and MDA-MB-436; and HER2-positive SK-BR-3. Human peripheral blood monocyte-derived 
immature DCs (imDCs) were co-cultured each of various breast cancer cell lines in the presence of poly (I:C). 
Each human breast cancer cell line was seeded on the culture plate 12 h before the co-culture under the mem-
brane insert with 0.4 μ m pores on which imDCs were loaded, designed for only soluble factors to freely move. 
In the presence of poly (I:C), all DCs co-cultured with various breast cancer cells undergone normal matura-
tion processes based on highly expressed co-stimulatory molecules, CD80, CD83 and CD86, and HLA-DR 
when compared with those expressed on mature DCs (mDCs) co-cultured with MCF-10A (mDC-MCF-10A) 
(Supplementary Fig. S3), although HLA-DR expression on mDC-MCF-10A was higher. We from here des-
ignated mDCs indirectly co-incubated with each of various cell lines as mDC-MCF-10A, mDC-MCF-7, 
mDC-MDA-MB-231, mDC-MDA-MB-436, or mDC-SK-BR-3. 2 days after the co-culture, we purified mDCs, 
and examined their chemotaxis and chemokinesis toward CCL19 in our 3D microfluidic device. Interestingly, 
we observed that the overall chemotaxis of mDCs co-cultured with breast cancer cells was significantly increased 
while no such enhanced chemotaxis was observed from mDC-MCF-10A compared with that of mDC only. 
Their enhanced chemotaxes were mainly mediated via significantly enhanced directional persistence (Fig. 2b,d), 
while the migration velocity was comparable in all groups (Fig. 2a,c). In addition, the increase in directional 
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persistence of mDCs interacted with luminal (mDC-MCF-7) or TNBC cell lines (mDC-MDA-MB-231 and 
mDC-MDA-MB-436) was more significant than that of mDCs co-incubated with HER2-overexpressing SK-BR-3 
(mDC-SK-BR-3) (Fig. 2b,d). Since the culture condition of MCF-10A cell requires additional substances such as 
insulin, epidermal growth factor (EGF) and hydrocortisone, and insulin and hydrocortisone are known to alter 
DC maturation and function27,28, we utilized an conditioned medium for maintaining all cell lines and DCs, and 
found no significant effects of the conditioned medium on the migratory properties of mDCs (Supplementary 
Fig. S4).
Enhanced chemotaxes of mDC-MDA-MB-231 and mDC-MDA-MB-436 were mediated by 
a highly up-regulated JNK/p-c-Jun signaling pathway. Since the chemotaxis of mDCs is mainly 
regulated via CCR7-CCL19 interaction, we examined whether breast cancer derived soluble factors increase 
the expression levels of CCR7 on mDCs. Unexpectedly, the levels of CCR7 expression on mDC-MCF-7, 
mDC-MDA-MB-436, and mDC-SK-BR-3 were not critically affected while its level was significantly decreased 
on mDC-MDA-MB-231 compared with that on mDC-MCF-10A (Fig. 2e,f). To further understand the highly 
enhanced directionality observed in the CCL19-induced chemotaxis of mDC-MCF-7, mDC-MDA-MB-231 or 
mDC-MDA-MB-436, in spite of the reduced or not affected CCR7 expression, their underlying mechanisms 
were investigated. Based on the previous studies showing the involvement of MAP kinases, such as ERK1/2, 
Figure 1. Migration of DCs under the CCL19 concentration gradient in the 3D microfluidic device. 
(a) Schematic view of a multilevel microfluidic device for a cell migration assay. A linear concentration 
gradient of CCL19 is formed across the cell-laden collagen gel. (b) Bright line images of mature DCs 
(mDCs) migrating toward CCL19. Trajectories of three cells over a period of 20 min are overlapped. Scale 
bar = 50 μ m. (c,d) Trajectories of mDCs in the absence (c) or presence (d) of CCL19. n = 40. The starting 
position of each cell is superimposed. The cells were imaged every 2 min and tracked for 2 h. (e) The cellular 
trajectory (solid arrowed line) was analyzed to calculate the velocity (s/t) and directional persistence (d/s) 
of the migrating cells, where s is the total migration distance, d is the displacement along the gradient axis, 
and t is the time. (f,g) Box-and-whisker plots of the velocity (f) and directional persistence (g) of immature 
DCs (imDCs) or mDCs. Data were calculated from the cellular trajectories. n ≥ 40. * * * P < 0.001.
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p38 and JNK in CCR7-mediated chemotaxis of DCs, independent of Rho pathways responsible for cell veloc-
ity29,30, activation of MAP kinases and Rho was analyzed before and after CCL19 treatment. Upon CCL19 stimu-
lation, we observed highly enhanced levels of phosphorylated (p)-JNK and p-c-Jun in mDC-MDA-MB-231 and 
Figure 2. Enhanced directional movement of breast cancer-affected mDCs toward CCL19. (a,b) Box-
and-whisker plots of the velocity (a) and directional persistence (b) of mature DCs (mDC only) or mDCs co-
incubated with MCF-10A (mDC-MCF-10A), MCF-7 (mDC-MCF-7), MDA-MB-231 (mDC-MDA-MB-231), 
MDA-MB-436 (mDC-MDA-MB-436) or SK-BR-3 (mDC-SK-BR-3) in response to CCL19. (c,d) Histograms 
of the velocity (c) and directional persistence (d) of mDC only, mDC-MCF-10A, mDC-MCF-7, mDC-
MDA-MB-231, mDC-MDA-MB-436 or mDC-SK-BR-3. The mean velocity and directional persistence of mDC 
only are indicated by a dotted line. n ≥ 70. (e) Flow cytometric analysis of CCR7 expression on the indicated 
groups. (f) Data represent mean ± s.e.m. of at least three independent experiments described in (e). Data was 
normalized by mDC only (value = 1). * P < 0.05 and * * * P < 0.001.
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mDC-MDA-MB-436 compared with those in mDC only or mDC-MCF-7 (Fig. 3a,b). Again, the expression level 
of p-JNK/total (T)-JNK or p-c-Jun/T-c-Jun was higher only in mDC-MDA-MB-231 and mDC-MDA-MB-436 
(Fig. 3c,d). The expression level of p-ERK/T-ERK was comparable in all groups (Fig. 3e), and p-38/T-38 expres-
sion was slightly higher in mDC-MDA-MB-231 (Fig. 3f). In the absence of CCL19 treatment, the expression 
levels of p-JNK/T-JNK, p-c-Jun/T-c-Jun, p-ERK/T-ERK and p-38/T-38 were comparable among the groups 
(Fig. 3c–f), suggesting that the enhanced JNK/c-Jun signaling pathway observed in mDC-MDA-MB-231 or 
mDC-MDA-MB-436 is dependent on CCL19 stimulation. We then compared the activity of RhoA, responsible 
for cell velocity, between mDC only and mDC-MDA-MB-231 in the presence or absence of CCL19, and found 
its expression levels were comparable between the two groups (Fig. 3g,h), consistent with our similar veloc-
ity data of all groups (Fig. 2a). These results suggest that the highly increased JNK/c-Jun signaling pathway in 
mDC-MDA-MB-231 or mDC-MDA-MB-436 is closely correlated with their enhanced directional movement 
toward CCL19.
Figure 3. CCL19 induced JNK/c-Jun signaling pathway is highly activated in mDC-MDA-MB-231 and 
mDC-MDA-MB-436. (a,b) Expression of MAP kinase molecules, JNK, c-Jun, ERK or p-38, in mDC only, 
mDC-MCF-7, mDC-MDA-MB-231 or mDC-MDA-MB-436 at 0 or 30 min after CCL19 treatment. (c,f) Data 
represent mean ± s.e.m. of the ratio of p-JNK/T-JNK (c), p-c-Jun/T-c-Jun (d), p-ERK/T-ERK (e) or p-p38/
T-p38 (f) from at least three independent experiments described in (a,b). (g) Activity of GTP-RhoA in mDC 
only or mDC-MDA-MB-231 at 0 or 2 min after CCL19 treatment. (h) Data represent mean ± s.e.m. of two 
independent experiments described in (g). Uncropped western blot images are shown in Supplementary Figs S7 
and S8a. p = phosphorylated, T = total. * P < 0.05 and * * P < 0.01.
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Inhibition of JNK signaling in mDC-MDA-MB-231 abolishes their enhanced directionality 
toward CCL19. To further confirm the data demonstrating that the JNK signaling pathway regulates the 
increased directional persistence of mDC-MDA-MB-231, we applied inhibitors of ERK, JNK, or p38 to mDC only 
or mDC-MDA-MB-231 followed by CCL19 treatment. The appropriate activity of a JNK inhibitor was confirmed 
by the markedly decreased expression of p-c-Jun/T-c-Jun in both mDC only and mDC-MDA-MB-231 (Fig. 4a,c). 
Interestingly, the formerly enhanced expressions of p-JNK/T-JNK and p-c-Jun/T-c-Jun in mDC-MDA-MB-231 
upon CCL19 stimulation was reduced to the level of those in mDC only after the JNK inhibitor treatment 
(Fig. 4a–c).
In our 3D microfluidic device, we found no significant difference between the migratory velocities of mDC 
only and mDC-MDA-MB-231 after the JNK inhibitor treatment (Fig. 4d). However, the inhibition of JNK activity 
was sufficient to completely abolish the increased directionality of mDC-MDA-MB-231 toward CCL19 (Fig. 4e). 
Interestingly, a higher concentration of the JNK inhibitor was required to suppress the enhanced directionality of 
mDC-MDA-MB-231 compared with that of mDC only (Fig. 4e), suggesting that the up-regulated JNK signaling 
(Fig. 3a,c) is crucial for the increased chemotaxis of mDC-MDA-MB-231. In 2D transwell assays with the JNK 
inhibitor, we again confirmed that the formerly increased migration of mDC-MDA-MB-231 toward CCL19 was 
dramatically decreased to the level slightly higher than that of mDC only (Supplementary Fig. S5a). In the case 
of p38 inhibitor assay, we observed decreased migration of mDC-MDA-MB-231 toward CCL19, but the level of 
reduction was much smaller than that caused by the JNK inhibitor (Supplementary Fig. S5b–d). We observed no 
significant effects of ERK inhibition on DC migration (Supplementary Fig. S5e–g). The inhibitors were not toxic 
to DCs at the concentrations we treated (Supplementary Fig. S6a,b), and there was no effect of the JNK inhibitor 
on the level of CCR7 expression on mDCs (Supplementary Fig. S6c,d). Taken together, these data clearly indicate 
that MDA-MB-231- or MDA-MB-436-derived soluble factors significantly increase the CCL19 induced chemot-
axis of DCs in a JNK signaling dependent manner.
mDC-MDA-MB-231 secrete pro-inflammatory cytokines and induce highly proliferative and 
activation-induced cell death (AICD)-resistant inflammatory T cells. Next, we questioned how 
mDC-MDA-MB-231 affects DC-mediated T cell immune responses. Cytokines secreted from DCs play a cru-
cial role in inducing T cell immune responses, which may result in pro- or anti-tumor immune responses31,32, 
Figure 4. The enhanced directionality of mDC-MDA-MB-231 toward CCL19 is significantly decreased by the 
inhibition of JNK activity. (a) The expressions of JNK and c-Jun molecules in mDC only or mDC-MDA-MB-231 in 
the presence or absence of a 30 μ M JNK inhibitor (SP600125) with or without CCL19 treatment. (b,c) Data represent 
mean ± s.e.m. of the ratio of p-JNK/T-JNK or p-c-Jun/T-c-Jun from three independent experiments described in  
(a). Uncropped western blot images are shown in Supplementary Fig. S8b. p = phosphorylated, T = total. (d,e) Box-
and-whisker plots of the velocity (d) and directional persistence (e) of mDC only or mDC-MDA-MB-231 treated 
with various concentrations (0, 30 or 100 μ M) of SP600125. n ≥ 40. * P < 0.05, * * P < 0.01 and * * * P < 0.001.
www.nature.com/scientificreports/
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thus we compared cytokines from mDC only and mDC-MDA-MB-231. We observed the slightly decreased 
level of cytokine IL-12 and markedly increased levels of pro-inflammatory cytokines IL-1β and IL-6 in 
mDC-MDA-MB-231 compared with those in mDC only (Fig. 5a).
To analyze how inflammatory DCs affect CD3+ T cell functions, we performed an allogenic mixed lymphocyte 
reaction, and observed significantly enhanced proliferation of CD3+ T cells that had been previously co-cultured 
with mDC-MDA-MB-231 compared with that of CD3+ T cells co-cultured with mDC only (Fig. 5b,c). Moreover, 
these highly proliferative allogenic T cells that had been induced by mDC-MDA-MB-231 were more resistant 
to AICD (Fig. 5d,e), and secreted significantly higher levels of inflammatory cytokines, such as IL-1β , IL-6 and 
IFN-γ (Fig. 5f). Taken together, these data show that MDA-MB-231-derived soluble factors affect DCs in such a 
way that these DCs not only up-regulate inflammatory cytokines, but also induce inflammatory CD3+ T cells that 
are more proliferative and less susceptible to AICD, leading to chronic inflammatory milieu, which may result in 
promotion of tumor growth.
Discussion
In this study, our 3D microfluidic device allows us to observe novel effects of various breast cancer cell lines on 
the chemotaxis of DCs toward CCL19. Interestingly, our results demonstrated a novel aspect of how the soluble 
factors of metastatic triple negative breast cancers (TNBCs, MDA-MB231 and MDA-MB-436) exploit DCs, lead-
ing to chronic inflammation. TNBC-derived soluble factors enhanced the CCL19 induced chemotaxis of mature 
DCs in a JNK signaling pathway dependent manner and generated inflammatory DCs which induce highly pro-
liferative and less apoptotic inflammatory T cells, resulting in high inflammatory milieu, of which condition may 
be positively correlated with breast cancer progression33.
Our findings provide novel insights into the various effects of tumor microenvironments on DC function. It 
is well-known that appropriate regulation of maturation and migration of DCs upon foreign stimulation is the 
first critical step in inducing antigen-specific adaptive immune responses34. Moreover, the quantity and qual-
ity of antigen-specific CD4+ T cell responses have been shown to be proportional to the migrated number of 
antigen-pulsed DCs into the secondary lymphoid organs35, suggesting that any hindrance in DC migration may 
be detrimental to induce anti-tumor responses. Therefore, it is not surprising that tumors evade host immunity 
by impairing the immunological function of DCs12,36. It is noteworthy that our study, suggesting the enhanced 
CCL19-induced chemotaxis of TNBC-affected DCs, is an alternative perspective on tumor evasion strategies, 
where tumors may manipulate host adaptive immune responses via accelerated migration of DCs.
We identified that the CCL19 induced directional movement of TNBC derived factor-interacted DCs was 
increased via the enhanced JNK signaling pathway. Using our 3D microfluidic device, we clearly showed that the 
enhanced migratory activity of TNBC-affected DCs is due to the facilitation of directional movement rather than 
the velocity of DCs. This 3D multilevel microfluidic device assay provided a simple and versatile way for studying 
cell migration in a well-controlled in vitro microenvironment. The multilevel microfluidic platform does not 
require bulky or superfluous equipment for either fabrication or operation, allowing a low-cost, biologist-friendly, 
and a reliable cell-based assay (Supplementary Fig. S1)23. Tracking individual cells in the microfluidic device ena-
bled us to extract meaningful features for quantitative analysis of directed movement of the cells24.
Interestingly, in comparison to a previous study that showed the involvement of co-operative interactions of 
ERK1/2, JNK and p38 in DC migration29, our microfluidic assay indicated that JNK inhibition alone was suffi-
cient to completely suppress the up-regulated directional movement of mDC-MDA-MB-231 (Fig. 4e). However, 
since the expression level of p-p38/T-p38 was slightly increased in mDC-MDA-MB-231 (Fig. 3f) and the treat-
ment of a p38 inhibitor resulted in the decreased chemotaxis of mDC-MDA231 toward CCL19 (Supplementary 
Fig. S5b–d), we do not exclude the possibility of co-operative interaction between JNK and p38 molecules in 
enhancing DC migration37. In addition, besides c-Jun, other JNK downstream molecules such as Paxillin and 
Spir, regulating adhesion or actin dynamics, respectively, may also have a role in cell chemotaxis of DCs38. In the 
case of breast cancer luminal types such as MCF-7 and SK-BR-3, we also observed the enhanced directionality of 
mDC-MCF-7 and mDC-SK-BR-3 toward CCL19. However, the enhanced chemotaxis of mDC-MCF-7 was not 
regulated by the JNK/c-Jun signaling pathway, thus further studies are required to investigate possible underlying 
mechanisms influenced by various types of breast cancer cells.
This study showed that mDC-MDA-MB-231 expressed significantly higher pro-inflammatory cytokines 
IL-1β and IL-6, and CD3+ T cells induced by mDC-MDA-MB-231 highly secreted profound pro-inflammatory 
cytokines, IL-1β , IL-6 and IFN-γ , and were highly proliferative and resistant to AICD. It is well-known that a 
chronic inflammatory niche in the host plays pivotal roles in the development and progression of various tum-
ors39. Previous studies demonstrated that increased IL-6 and IL-1β cytokines are correlated with tumor inva-
siveness and worse prognosis, particularly in metastatic breast cancer patients31,40,41. Another recent study also 
demonstrated that IL-6 cytokine can promote the growth of triple negative breast cancer cells and support their 
chemotherapy resistance or resistance to apoptosis42. In addition, evolutionary walks driven by IFN-γ can be 
adapted by tumor cells to lead tumor editing and selection of resistant clones, thereby promoting the tumor 
growth or development43. In contrast to previous reports demonstrating suppressed or dysfunctional T cell activ-
ity in various tumor microenvironments44, our results implicated stimulatory and inflammatory T cells, indi-
cating an alternative point of view for understanding the diversity and complexity of tumor microenvironments 
manipulating host anti-tumor immunity. However, we do not exclude the possibility of IFN-γ secreted from 
cytotoxic CD8+ T cells responsible for tumor rejection as well as other roles of IL-1β and IL-6 cytokines in com-
plex immune networks31,45. Further studies are necessary to identify specific T cell subsets with distinct cytokine 
profiles induced by TNBC-affected DCs.
Previous studies reported that several soluble factors such as VEGF, IL-6, IL-10 and TGF-β secreted from dif-
ferent types of cancers may induce dysfunctional DCs46,47. In addition to those factors, we screened other possible 
breast cancer-derived factors that may be responsible for the enhanced directionality of mDC-MDA-MB-231 
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in a JNK signaling dependent manner, and found IL-1β and IL-6 cytokines, known to be related in enhanc-
ing the JNK signaling pathway48,49, are highly expressed in MDA-MB-231 and MBA-MB-436 compared with 
those in MCF-10A or MCF-7. However, when we suppressed the expression level of each or both cytokines in 
MDA-MB-231 by half via utilizing each cytokine specific shRNAs, neither the formerly enhanced chemotaxis nor 
Figure 5. mDC-MDA-MB-231 expressing pro-inflammatory cytokines induces T cells to more proliferate and 
resistant to activation-induced cell death. (a) The relative mRNA expressions of IL-1β, IL-6, and IL-12 in imDC, 
mDC only or mDC-MDA-MB-231. (b) Flow cytometric analysis of carboxyfluorescein succinimidyl ester (CFSE)-
labeled CD3+ T cell only and CFSE-labeled CD3+ T cells co-cultured either with mDC only or mDC-MDA-MB-231. 
(c) Data represent mean ± s.e.m. of three independent experiments described in (b). (d) Flow cytometric analysis of 
propidium iodide (PI) and annexin V staining of CD3+ T cells activated by CD3 and CD28 antibodies in the presence 
of IL-2; these cells had previously been co-cultured either with mDC only or mDC-MDA-MB-231. (e) Data represent 
mean ± s.e.m. of three independent experiments described in (d). (f) The cytokine levels of IL-1β , IL-6 and IFN-γ 
secreted from CD3+ T cells only and CD3+ T cells co-cultured either with mDC only or mDC-MDA-MB-231. Data 
represent mean ± s.e.m. of three independent experiments (a,f). * P < 0.05, * * P < 0.01 and * * * P < 0.001.
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the JNK expression of mDC-MDA-MB-231 was critically affected (Data not shown). Further studies are required 
to examine the effects of various and combined breast cancer cell-derived soluble factors on DC migration as well 
as following underlying mechanisms in DCs to better understand the enhanced DC chemotaxis.
In conclusion, our study proposed a new tumor evasion strategy elucidating how the soluble factors of TNBCs 
manipulate DCs to induce dysfunctional T cells that may support tumor development. Future preclinical studies 
may provide a rationale for blocking the JNK signaling pathway in DCs of metastatic breast cancer patients to 
reduce impaired DC-mediated immune responses, and also may suggest new insight in understanding the effects 
of the tumor microenvironment on immune responses.
Methods
Design and fabrication of microfluidic devices. A microfluidic device was fabricated for the on-chip 
chemotaxis assays. The microfluidic device had three different levels—a 100 μ m high main channel, two 
200 μ m high side-channels adjacent to the main channel, and two 300 μ m high side-chambers for loading media. 
The width of each channel was 1 mm. The multilevel microfluidic device was fabricated by using triple-layered 
adhesive tape as a master for molding PDMS (Supplementary Fig. S1). The tapes were cut into the desired design 
for each level using a cutting plotter (CE3000-60; Graphtec Corp) and stacked layer-by-layer. A 10:1 mixture of 
the PDMS prepolymer and the curing agent (Sylgard 184 Silicone Elastomer Kit; Dow Corning) was poured onto 
the master, and cured in an oven at 65 °C for 2 h. The PDMS was peeled off from the master, and diced. After holes 
were punched, the PDMS structure was bonded onto a 25 mm-diameter glass coverslip by oxygen plasma treat-
ment of both the PDMS and the glass surfaces.
Preparation of human immature dendritic cells. Peripheral blood mononuclear cells (PBMCs) were 
isolated from the blood of healthy donors obtained from Ulsan Blood Center, Ulsan, South Korea, by den-
sity gradient centrifugation on Ficoll-Paque Plus (GE Healthcare) according to Institutional Review Board of 
the Ethics Committee (IRB: 02-2011-001.) CD14+ monocytes were then isolated by positive selection using 
magnetic-activated cell sorting (MACS; Miltenyi Biotec). CD14+ monocytes were cultured in RPMI 1640 
medium with 5% FBS, 1% penicillin/streptomycin, 1000 units/ml GM-CSF (Invitrogen), and 1000 units/ml IL-4 
(Invitrogen) for 72 h, and then the same concentrations of GM-CSF and IL-4 were added for an additional 48 h.
Cell line maintenance. Epithelial MCF10A, luminal MCF7, metastatic triple negative breast can-
cer MDA-MB-231 or MDA-MB-436, and HER2-overexpressing SK-BR-3 cells were purchased from the 
American Type Culture Collection. MCF-10A cells were cultured in DMEM/F12 media with 5% horse serum, 
1% antibiotic-antimycotic solution, EGF (20 ng/ml), hydrocortisone (500 ng/ml), and insulin (10 μ g/ml). 
MCF-7, MDA-MB-231 and MDA-MB-436 cells were cultured in RPMI 1640 medium with 5% FBS and 1% 
antibiotic-antimycotic solution, and SK-BR-3 cells were cultured in DMEM medium with 10% FBS and 1% 
antibiotic-antimycotic solution. The cells were maintained at 37 °C in a 5% CO2 humidified incubator. When can-
cer cells were co-cultured with DCs, we utilized the conditioned media, RPMI 1640 medium with 5% FBS, EGF 
(3.3 ng/ml), hydrocortisone (83 ng/ml), insulin (1.67 μ g/ml) and 1% antibiotic-antimycotic solution.
Co-culture of DCs with tumor cells in vitro. Each of various cancer cell lines was seeded in a 6-well plate 
at 0.5 × 106 cells per well 12 h before the co-culture experiment. Then, a transwell insert with a 0.4-μ m pore size 
membrane was placed onto the plate, and 1 × 106 immature DCs were loaded into the upper well of the transwell 
chamber. The immature DCs were co-cultured with each of cancer cell lines for 48 h in the presence of 25 μ g/ml 
poly (I:C) (Invivogen). Immature DCs cultured alone in the transwell chamber with 25 μ g/ml poly(I:C) were used 
as control (mDC only).
Microfluidic cell migration assays. The PDMS–glass devices were sterilized with 70% ethanol under a 
laminar flow hood with ultraviolet exposure for more than 30 min. 3 mg/ml purified bovine collagen solution 
(PureCol; Advanced BioMatrix) containing DCs was injected into the main channel, followed by polymeriza-
tion in a 5% CO2, 37 °C incubator, for around 45 min. 1% agarose (Low gelling temperature agarose; Sigma–
Aldrich Corp) solution was then injected into the side-channels adjacent to the main channel. After gelation of 
the agarose at room temperature, 3 μ g/ml CCL19 (R&D Systems) in cell culture medium and blank cell culture 
medium were loaded into the respective side-chambers (Fig. 1a). The devices were mounted in a custom-built 
live cell chamber, in which 6 devices could be imaged using an EMCCD camera (Andor iXon 897; Till Photonics 
GmbH) under controlled temperature and CO2 conditions, on the motorized stage of an inverted microscope 
(IX81-ZDC; Olympus Corp). The devices were incubated for 2 h in the live cell chamber to allow formation of 
a linear CCL19 gradient across the collagen gel and to allow the cells to stabilize. For MAP kinase inhibition 
experiments on-chip, we utilized DCs (0.25 × 106 cells) that had been previously co-cultured with or without 
MDA-MB-231 (0.5 × 106 cells) in the presence of poly (I:C) for 2days in our co-culture system, and inhibitors of 
JNK (SP600125, 30 or 100 μ M), p38 (PD98059, 20 μ M), or ERK (U0126, 10 μ M), purchased from Calbiochem, 
were added to the collagen gel prior to mixing with the DCs. To maintain the concentrations of each inhibitor 
in the microfluidic channel, media mixed with particular concentrations of each inhibitor were loaded into the 
side-chambers. Time-lapse images of the cells were taken in bright field every 2 min using a 10× objective, for a 
total duration of 2 h.
Transwell cell migration assays. mDCs (2 × 105 cells) were loaded into the upper well of an transwell 
insert with an 8-μ m pore membrane (BD Biosciences) in 100 μ l of media, and 600 μ l of media with 100 ng/ml 
CCL19 was added into the bottom well of the insert. After 4 h of incubation in a 37 °C incubator, the number of 
mDCs that had migrated to the bottom well was counted by flow cytometry. For the inhibitor assays, mDC only 
or mDC-MDA-MB-231 was treated with the inhibitor of JNK (SP600125, 30 μ M), p38 (PD98059, 20 μ M) or ERK 
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(U0126, 10 μ M) for 1 h in a 37 °C incubator, and the transwell migration assay was performed as described before 
with the inhibitor present in both the upper and bottom wells of the insert.
Flow cytometry. Cells were washed with fluorescent-activated cell sorting (FACS) buffer (2% FBS in PBS) 
twice, and were then stained with antibodies at 4 °C for 30 min. Data were acquired using a FACS Calibur or 
LSRfortessa (BD Biosciences) and analyzed with a FlowJo software (Tree Star Inc., Ashland, OR). Median fluores-
cence intensity (MFI) data were shown after the subtraction of corresponding isotype control values. Antibodies 
used in flow cytometry as follows: CD11c (B-ly6), CD80 (L307.4), CD83 (HB15e), CD86 (IT2.2), and HLA-DR 
(TU36) were purchased from BD Biosciences, CCR7 (3D12) and Rat IgG2a were purchased from eBioscience, 
and CD3 (HIT3a) and CD28 (CD28.2) were purchased from BioLegend.
Western blotting. mDC only, mDC-MCF-7, mDC-MDA-MB-231 and mDC-MDA-MB-436 were treated 
with 100 ng/ml CCL19 for 0 or 30 min in a 37 °C incubator, followed by western blotting (WB) assays. For inhib-
itor tests, mDC only or mDC-MDA-MB-231 was treated with each of 30 μ M JNK, 10 μ M ERK or 20 μ M p38 
inhibitor for 1 h, and then the cells were treated with 100 ng/ml CCL19 for an additional 30 min in a 37 °C incu-
bator. Antibodies used in western blotting as follows: p = phosphorylated, T = total, p-ERK1/2 (Thr202/Tyr204), 
T-ERK1/2 (137F5), p-JNK (Thr183/Tyr185) and p-p-38 (Thr180/Tyr182) were purchased from Cell Signaling, 
T-JNK (37/pan-JNK/SAPK1) and T-p38 (27/p38α /SAPK2a) were purchased from BD biosciences, p-Jun (KM-1) 
and T-Jun (H-79) were purchased from Santa Cruz, and β -actin was purchased from Ambion. GTP-RhoA was 
blotted using a Rho Activation Assay Biochem kit (Cytoskeleton). Briefly, mDC only or mDC-MDA-MB-231 
was treated with 100 ng/ml CCL19 for 0 or 2 min. The cells were immediately lysed and then incubated with 
rhotekin-RBD beads to pull down GTP-RhoA molecules, followed by a western blot assay.
Allogenic mixed lymphocyte reaction. CD3+ T cells were isolated from peripheral blood mononuclear 
cells by using a pan T cell isolation cocktail kit (Miltenyi Biotec) and MACS. CD3+ T cells (1 × 105 cells) labeled 
with carboxyfluorescein succinimidyl ester (CFSE, Invitrogen) were co-cultured either with 0.2 × 105 cells of 
mDC only or mDC-MDA-MB-231 for 4 days, and the percentage of divided cells was measured by flow cytome-
try. For the activation-induced cell death (AICD) assay, CD3+ T cells that had been previously co-cultured either 
with mDC only or mDC-MDA231 were purified and allowed to rest for 1 day in the presence of 50 units/ml 
IL-2 (BioLegend). Then, the CD3+ T cells were stimulated with plate-bound anti-CD3 (5 μ g/ml, BioLegend) and 
soluble anti-CD28 (1 μ g/ml, BioLegend) antibodies in the presence of 50 units/ml IL-2 for additional 2 days. The 
stimulated CD3+ T cells were stained with PI (BD Bioscience) and annexin V (BD Bioscience), and analyzed by 
flow cytometry.
Quantitative RT-PCR analysis. CD3+ T cells were co-cultured either with mDC only or 
mDC-MDA-MB-231 and then isolated by magnetic-activated cell sorting (MACS). Total RNA was extracted 
with Trizol (Invitrogen), and cDNA was synthesized using the cDNA Synthesis kit (NEB). A Light Cycler 
480 II (Roche) was used to perform a SYBR Green-based qRT-PCR experiment. The house-keeping 
gene, GAPDH, was used for normalization. The qRT-PCR primers are as follows: human IL-1β , forward 
5′-ACATCAGCACCTCTCAAGCA-3′ reverse 5′ -AGTCCACATTCAGCACAGGA-3′ ; human IL-6, forward 
5′-CTGGTCTTTTGGAGTTTGAGGT-3′ reverse 5′ -GGAACTGGATCAGGACTTTTGT-3′ ; human IL-12, for-
ward 5′ -CCACAAAAATCCTCCCTTGA-3′ reverse 5′ -AGGGACCTCGCTTTTTAGGA-3′ ; human GAPDH, 
forward 5′ -TGACAACTTTGGTATCGTGGA-3′ reverse 5′ -CAGTAGAGGCAGGGATGATGT-3′ . Melting tem-
perature was 60 °C.
Quantification of cytokines. Various cytokines in cultured supernatants were measured using a 
Spectramax Plus 384 (Molecular Devices) following a sandwich-based ELISA protocol (BioLegend).
Statistical analysis. Results are expressed as mean ± s.e.m. Data normality was tested with Lilliefors test. 
If the data have a normal distribution, Student’s t-test was used to identify statistically significant differences 
between the groups. Otherwise, the Mann-Whitney test was used. P-values < 0.05 were considered as statistically 
significant: *P < 0.05, **P < 0.01, and ***P < 0.001. Microsoft Excel and Prism Graphpad were used for the statis-
tical analysis and graphing.
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